泛昔洛韦治疗复发性生殖器疱疹疗效评价

Evaluation of curative effect by famciclovir in the treatment of recurrent genital herpes

目的评价泛昔洛韦治疗复发性生殖器疱疹的疗效。方法 86例生殖器疱疹患者,随机数表法分为对照组和研究组,每组43例。对照组患者服用阿昔洛韦进行治疗,研究组患者服用泛昔洛韦进行治疗,观察并比较两组患者的临床疗效以及不良反应发生情况。结果经治疗,研究组治疗总有效率为97.7%,对照组患者为86.0%,研究组治疗总有效率明显高于对照组(P<0.05)。研究组患者治疗后1年内复发率为51.2%,对照组患者复发率为83.7%,研究组患者1年复发率低于对照组(P<0.05)。治疗后,研究组患者止疱时间为(1.53±1.23)d,结痂时间为(4.55±1.37)d,明显早于对照组的(3.09±1.02)、(7.19±1.18)d,差异具有统计学意义(P<0.05)。两组患者不良反应发生率比较差异无统计学意义(P>0.05)。结论泛昔洛韦治疗复发性生殖器疱疹疗效显著,复发率低,且无严重不良反应,建议临床上推广应用。

Objective To evaluate curative effect by famciclovir in the treatment of recurrent genital herpes. Methods A total of 86 patients with genital herpes were divided by random number table into control group and research group, with 43 cases in each group. The control group received acyclovir for treatment, and the research group received famciclovir for treatment. Observation and comparison were made on clinical effect and occurrence of adverse reactions between the two groups. Results After treatment, the research group had total effective rate in treatment as 97.7%, which was 86.0% in the control group. The research group had obviously higher total effective rate in treatment than the control group（P〈0.05）. The research group had recurrence rate in 1 year after treatment as 51.2%, and the control group had recurrence rate as 83.7%. The research group had lower recurrence rate in 1 year after treatment than the control group（P〈0.05）. After treatment, the research group had herpes remission time as（1.53±1.23） d and incrustation time as（4.55±1.37） d, which were all earlier than（3.09±1.02） and（7.19±1.18） d in the control group, and their difference had statistical significance（P〈0.05）. There was no statistically significant difference of incidence of adverse reactions between the two groups（P〈0.05）. Conclusion Famciclovir shows excellent curative effect in treating recurrent genital herpes, with low recurrence rate and no severe adverse reactions. This method is recommended for clinical promotion and application.